Mark Bennioff, chairman and CEO of Salesforce.com, discusses the exciting revenue growth and its "awesome" quarterly numbers, with Mad Money's Jim Cramer. Bennioff says it's never been more important for all businesses to connect with their customers in a new way.» Read More
CNBC's Jim Cramer explains why Sterne Agee is watching DSW closely, and also how investors should play Anadarko Petroleum.
Jim Cramer explains what to watch ahead of the open, including Chipotle and El Pollo Loco.
Jim Cramer sees plenty of money making opportunities scattered across almost every sector of the market. Here's what's on his calendar.
Dissecting the earnings of AMD and Intel and excuses made by management, with Mad Money host Jim Cramer.
Mad Money host Jim Cramer shares his take on how the market is judging the performances of Amazon and Starbucks.
Mad Money host Jim Cramer looks ahead to earnings, IPOs and economic data that may impact the market next week.
CNBC's Melissa Lee and the Options Action traders discuss the stocks they'll be watching next week.
Managing a winning trade on social stocks, with CNBC's Melissa Lee and the Options Action traders.
Dissecting bearish bets on energy, with CNBC's Melissa Lee and the Options Action traders.
Why industrials are lagging, with CNBC's Melissa Lee and the Options Action traders.
Testing out Amazon's Fire Phone and its "Firefly" feature, with Mashable's Lance Ulanoff.
The good, the bad, and the ugly of earnings season, with CNBC's Melissa Lee and the Options Action traders.
The Fast Money traders share their final trades of the day.
The Fast Money traders take a look at today's biggest market movers.
The FM traders discuss the IPO and momentum of El Pollo Loco.
FM trader Pete Najarian notices unusual activity in the cosmetics space.
Discussing the profitability of Amazon, with the Fast Money traders.
CNBC's Bertha Coombs reports which insurance stocks are hurting from the high cost of hepatitis C Sovaldi.
The market has been hitting record after record, and its run is only going to continue, two investing pros told CNBC Friday.
CNBC's Bertha Coombs reports which insurance stocks are feeling the pressure from high drug costs. FMHR trader Stephen Weiss advises investors to stick with Gilead.